BrainsWay presented new data showing that their SWIFT™ accelerated Deep Transcranial Magnetic Stimulation (Deep TMS) protocol achieves over 80% remission rates in patients with Major Depressive Disorder one year after treatment. The study also found a drop in severe functional impairment from 85% to 0%, highlighting significant improvements in patients' daily functioning and quality of life. These results confirm the long-term effectiveness and durability of the accelerated Deep TMS treatment, offering a faster and sustained alternative to traditional protocols. This advancement could expand treatment options for depression with fewer clinic visits and lasting benefits.
Nyxoah SA has issued 55,232,558 new ordinary shares as part of a previously announced public offering, increasing the total number of shares with voting rights to 99,926,284. This move follows a private placement to qualified investors outside the U....
BIO-key International, a leader in biometric authentication, received a Nasdaq notice for failing to file its quarterly 10-Q report on time for Q1 2026. Nasdaq's notice indicates the company's compliance with listing rules is under review, and a hear...
Fundstrat Capital completed the May 2026 quarterly rebalance of its Granny Shots US Small- & Mid-Cap ETF, adding 10 new stocks such as First Solar, Zoom, and Credo Technology, while removing eight others. The ETF follows a strategy requiring stocks t...
Navan Inc. reported better-than-expected Q1 earnings with a profit of $0.08 per share versus a loss estimate, and revenue of $220.23 million beating forecasts. Key growth drivers included a 41% rise in usage revenue and a 50% increase in Gross Bookin...
J.Jill is undergoing a strategic shift to expand its customer base in the women's apparel market. Despite a 6% revenue decline to $144.43 million in Q1, the company beat earnings expectations with $0.45 per share. Analyst Jefferies reaffirmed a "Buy"...
